You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Autoimmune
US FDA has Granted Priority Review of the Teprotumumab Biologics License Application for the Treatment of Active Thyroid Eye Disease
Login
Username:

Password:


Related Headlines

Antengene presents first ATG-207 preclinical data at EULAR 2026

Gilead and Lakefront complete Ouro Medicines acquisition to expand autoimmune disease pipeline

Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz

HotSpot Therapeutics presents preclinical data from small molecule IRF5 inhibitor programme at EULAR 2026

Circio and GenAssist announce gene therapy research collaboration for muscle diseases and in vivo cell therapy

CellCarta partners with Sonic Healthcare to commercialise companion diagnostics through Lab Network

Accro Bioscience completes USD50m Series C financing

Mabwell's clinical trial application for 9MW5211 cleared by US FDA

Curocell secures full approval for RIMQARTO to enter CAR-T therapy market

HUTCHMED secures priority review for sovleplenib NDA in China

Johnson & Johnson IMAAVY (nipocalimab-aahu) granted FDA Priority Review as potential treatment for wAIHA

Circio partners with Acuitas to evaluate in vivo CAR-T cell therapy technology

Asgard Therapeutics appoints chief medical officer

Thermo Fisher Scientific unveils CHOvantage GS Kit to speed biologics development

Galapagos and Gilead expand collaboration to advance T cell engager programme

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026